Global airway disease: mepolizumab simultaneously improves outcomes in severe CRSwNP and asthma
Rhinology Journal · 2024
DOI: 10.4193/rhin24.337 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Rhinology Journal, 2024. Verfasst von J Mullol und 9 weiteren Autor:innen. Beteiligte Einrichtung: Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic Barcelona, IDIBAPS, CIBERES, Barcelona, Catalonia, Spain. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Asthma, Rhinitis, Nasal Polyps. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Chronic rhinosinusitis with nasal polyps (CRSwNP) often co-exists with asthma and non-steroidal anti-inflammatory drug- exacerbated respiratory disease (N-ERD), creating a more severe phenotype and an additional burden compared with CRSwNP disease alone (1-3). The relationship between these diseases in terms of shared immunological disbalance has been coined in the literature as ‘global airway disease’ or ‘unified airway disease’ and requires integrated treatment strategies (4-6). Our post hoc analysis of the Phase III randomised, double-blind, placebo-controlled, multicentre SYNAPSE study (GSK ID: 205687; NCT03085797 (7)) assessed the efficacy of mepolizumab, an anti-interleukin-5 monoclonal antibody, in simultaneously improving both CRSwNP and asthma outcomes versus placebo. By utilising a combined measure that accounts for quality of life, sinonasal symptoms and asthma control, we aimed to validate the potential of mepolizumab as an effective therapeutic option for global airway disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic Barcelona, IDIBAPS, CIBERES, Barcelona, Catalonia, Spain.
- Department of Otorhinolaryngology Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen, Denmark.
- Department of ORL, AHEPA University Hospital, Thessaloniki, Greece.
- Allergy Unit, Hospital Regional Universitario de Malaga, Allergy group, IBIMA-Plataforma BIONAND. RICORS Inflammatory Diseases. Malaga, Spain.
- Specialty Care Unit, Medical Affairs, GSK, Madrid, Spain.
- Respiratory Biostatistics, GSK, Warren, NJ, USA.
Zitieren
APA
Mullol, J., Backer, V., Constantinidis, J., Eguiluz-Gracia, I., Moure, A. L., Cuervo-Pinto, R., Zhang, L., Shah, P., Kerr, W., & Hellings, P. (2024). Global airway disease: mepolizumab simultaneously improves outcomes in severe CRSwNP and asthma. Rhinology Journal. https://doi.org/10.4193/rhin24.337
Vancouver
Mullol J, Backer V, Constantinidis J, Eguiluz-Gracia I, Moure AL, Cuervo-Pinto R, et al. Global airway disease: mepolizumab simultaneously improves outcomes in severe CRSwNP and asthma. Rhinology Journal. 2024. doi:10.4193/rhin24.337
BibTeX
@article{Mullol2024,
author = {Mullol, J and Backer, V and Constantinidis, J and Eguiluz-Gracia, I and Moure, A L and Cuervo-Pinto, R and Zhang, L and Shah, P and Kerr, W and Hellings, P},
title = {Global airway disease: mepolizumab simultaneously improves outcomes in severe CRSwNP and asthma},
journal = {Rhinology Journal},
year = {2024},
doi = {10.4193/rhin24.337}
}
EUVIMED